STAAR Surgical Q1 2026: Early Signs Of A Durable Turnaround
STAAR Surgical Company reported significant growth in its first quarter of 2026, with a 119% increase in revenue year-over-year. The company achieved a net income of $5.2 million, driven by a rebound in the Chinese market and increased adoption of its EVO+ ICL product. Despite high valuations, STAAR is expanding its market share in lens-based refractive surgery as the laser market contracts.
- ▪STAAR Surgical's revenue reached $93.5 million in Q1 2026, marking a 119% increase compared to the previous year.
- ▪The company reported a net income of $5.2 million, indicating a positive turnaround.
- ▪Factors contributing to growth include a rebound in the Chinese market and the rapid adoption of the EVO+ ICL product.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Earnings Analysis","item":"https://seekingalpha.com/earnings/earnings-analysis"},{"@type":"ListItem","position":3,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4905656-staar-surgical-1q26-early-signs-of-a-durable-turnaround"},"author":{"@type":"Person","name":"Petri Dish…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
